Post

New research · Ophthalmology
Scientific reports · 4d
Randomized trialScientific reports · 2026

A multinational randomized clinical trial of an eye-tracking-based binocular amblyopia treatment in children aged 4-9 years.

Oren Yehezkel, Tamara Wygnanski-Jaffe, Burton J Kushner … The CureSight Pivotal Trial Group
Read paper
OphthalmologyRandomized trial

In children completing therapy, eye-tracking treatment improved vision more than patching

A multinational randomized clinical trial of an eye-tracking-based binocular amblyopia treatment in children aged 4-9 years.

Oren Yehezkel … The CureSight Pivotal Trial Group
Scientific reports · 2026
Purpose

This randomized controlled study compared efficacy and safety of a novel binocular, eye-tracking-based home amblyopia treatment (CureSight) to patching.

Methods

S.) enrolled 197 children aged 4 to < 9 years with anisometropic, small-angle strabismic, or mixed-mechanism amblyopia at 15 academic/community sites (modified intent-to-treat); 156 completed ≥ 60% of prescribed dosage (per-protocol).

n = 197 children
Results

kids using CureSight home therapy saw better vision gains than patchers

MD 0.03 (95% CI -0.01 to 0.06)
null = 0-0.010.06
CI crosses the null - not significant
More results

Three cohorts (China, Israel, U.

CureSight: 90 min/day, 5 days/week for 16 weeks (120 h); patching: 2 h/day, 7 days/week (224 h).

In the modified intent-to-treat dataset, visual acuity improvement from baseline to week 16 in the binocular group was noninferior to the patching group (0.028 logMAR; 95% CI - 0.007 to 0.063).

More results

There was no significant between-group difference in the magnitude of improvement in stereoacuity in either dataset.

“
Conclusion

Overall, CureSight was noninferior to patching in these amblyopia types and yielded better visual outcomes in children completing ≥ 60% dosage, supporting binocular therapy as an additional first-line option.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving